OnKure Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that OnKure Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($14.70M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($15.39M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($15.39M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($15.93M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($15.93M) | May 6, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($15.93M) | Nov 6, 2025 |
| Q2 | 2025 | Dec 31, 2024 | ($17.44M) | Aug 12, 2025 |
| Q1 | 2025 | Dec 31, 2024 | ($17.44M) | May 6, 2025 |
| Q3 | 2025 | Dec 31, 2024 | ($17.44M) | Nov 6, 2025 |
| Q2 | 2025 | Sep 30, 2024 | ($11.56M) | Aug 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($11.56M) | Nov 6, 2025 |
| Q1 | 2025 | Sep 30, 2024 | ($11.56M) | May 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($14.14M) | Nov 6, 2025 |
| Q1 | 2025 | Jun 30, 2024 | ($14.14M) | May 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($14.14M) | Aug 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($9.54M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($9.54M) | May 6, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($9.54M) | Nov 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($19.20M) | Nov 7, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($19.53M) | Nov 7, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($15.50M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($16.32M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($17.00M) | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($11.51M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($14.34M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($9.83M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($20.89M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($21.04M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.12M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($13.84M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($12.43M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.02M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($12.75M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($9.23M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($7.21M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.10M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($3.70M) | Aug 11, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($4.50M) | May 20, 2021 |